Archive for the ‘Medical’ Category

Study: Women with Early-Stage Breast Cancer May Not Need Chemotherapy

Posted By on June 5th, 2018 at 9:36 am | 0 comments.

According to a recent study, thousands of women with early-stage breast cancer do not need chemotherapy as part of their treatment regimen. The results of the largest ever breast cancer treatment trial, the TAILORx study, were published this week in the New England Journal of Medicine. Researchers say the trial found evidence that 70 percent of early-stage breast cancer patients will receive no benefit from chemotherapy. The article goes on to say those patients would effectively be treated with endocrine therapy alone. The data indicated that some women 50 and younger might benefit from chemo even if gene-test results suggested otherwise. It is not clear why.

“This is a game-changer. It’s truly groundbreaking. Now, thousands of women will not have to undergo toxic chemotherapy treatment with its unwanted side effects,” said PBCC President and Founder Pat Halpin-Murphy. “The results of this clinical trial will change the way oncologists treat breast cancer every day here in Pennsylvania and across the country.”

In order to conduct the TAILORx study, researchers examined results of the Genomic Health Oncotype DX test which provides a score for the patient’s risk of recurrence. The clinical trial found that, in patients who received a score of 11 to 25, chemotherapy was not necessary. Investigators conducted gene tests on tumor samples to identify women who could skip chemo and take drugs like tamoxifen that block estrogen or stop the body from producing estrogen (endocrine therapy). Drugs like tamoxifen have been proven to reduce the risk of recurrence in breast cancer survivors.

Today, 37 women will be diagnosed with breast cancer in Pennsylvania, and 140,000 PA women are currently living with the disease. Early-stage breast cancer makes up half of all breast cancer diagnoses.

CLICK HERE to read the complete New England Journal of Medicine article.

 

NEW Recommendations for Breast Cancer Screening

Posted By on May 11th, 2018 at 1:32 pm | 0 comments.

 

If you are considered at higher-than-average risk for breast cancer or you have dense breast tissue, the American College of Radiology (ACR) now recommends you get an annual screening MRI in addition to a mammogram. The new recommendations, published on DenseBreast-Info.org and in the Journal of the American College of Radiology, call for MRI if a woman is considered high risk.
The ACR continues its previous recommendations, supporting MRI beginning at age 25 for women with a BRCA1 mutation.

Women are considered high-risk if they:

  • Have dense breast tissue
  • Have a family history of breast cancer
  • Have been diagnosed with breast cancer by age 50

The American College of Radiology also recommends that all women, especially black women and those of Ashkenazi Jewish descent, be evaluated for breast cancer risk no later than age 30 so that a “higher risk can be identified and [the woman] can benefit from supplemental screening.”

    

FDA Approves Pill for Metastatic Breast Cancer

Posted By on November 7th, 2017 at 10:06 am | 0 comments.

Patients with metastatic breast cancer have a new FDA-approved treatment option. Federal regulators approved the drug, Verzenio, which blocks enzymes that promote the growth of cancer cells for women with HR-positive, HER2-negative breast cancer. This new drug is targeted specifically for survivors who have not responded to hormone therapy.

To read the complete article, click here.

 

Study: Pregnancy After Breast Cancer Does Not Increase Chance of Recurrence

Posted By on July 11th, 2017 at 3:07 pm | 0 comments.

Having a child after breast cancer treatment does not make you more likely to have a recurrence, researchers say. According to a recent study presented at the 2017 American Society of Clinical Oncology (ASCO) Conference. Researchers profiled more than 1,200 women under the age of 50 who were diagnosed with non-metastatic breast cancer before 2008. More than 300 of the women who participated became pregnant following treatment. The research team then matched each patient who became pregnant with three patients who had similar cancer characteristics, but did not become pregnant. After 10 years from the diagnosis, the research team found no difference in recurrence rate between women who became pregnant and those who did not.

Many survivors with ER-positive cancer are concerned with the need to stop post-surgery hormone therapy before they try to get pregnant (therapy that helps to prevent recurrence). Researchers recommend patients speak with their doctors when determining how long to wait before becoming pregnant if they receive hormone therapy.

Want to learn more? Read the complete study, click here.